---
title: "FDA Rejects Akeso's Bispecific: PFS Was Not Enough"
url: https://drugnews.com.tw/articles/2026-11-17-akeso-summit-ivonescimab-fda-crl-overall-survival-en.html
date: 2026-11-17
lang: en
category: "商業分析系列"
tags: ["Akeso","Summit Therapeutics","ivonescimab","FDA","PD-(L)1×VEGF"]
summary: "On November 15, 2026, Summit announced an FDA complete response letter for ivonescimab. The HARMONi primary OS analysis yielded p=0.057, missing the prespecified 0.0448 threshold."
json: https://drugnews.com.tw/articles/2026-11-17-akeso-summit-ivonescimab-fda-crl-overall-survival-en.json
publisher: Drugnews｜藥時事 (https://drugnews.com.tw/)
---
## 三句看懂

- On November 15, 2026, Summit announced an FDA complete response letter for ivonescimab. HARMONi primary OS yielded p=0.057, missing the 0.0448 threshold.
- The original Akeso license was worth up to $5 billion. Following the 2024 expansion, cumulative upfront payments reached $515 million, with up to $4.555 billion in milestones.
- HARMONi-3 squamous-cohort primary PFS and early interim OS analyses are expected in Q4 2026; non-squamous PFS analysis is expected in H1 2027.

## 關鍵數字（附來源）

| 項目 | 數值 | 日期 | 來源 |
|---|---|---|---|
| Summit announcement of an ivonescimab CRL | 2026-11-15 date | 2026-11-15 | https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx |
| HARMONi enrollment and enrollment in China | 438,273 patients | 2025-09-07 | https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival |
| HARMONi primary PFS reduction in progression or death risk | 48 % | 2025-09-07 | https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival |
| HARMONi primary OS reduction in death risk | 21 % | 2025-09-07 | https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival |
| HARMONi primary OS p-value and significance threshold | 0.057,0.0448 p | 2025-09-07 | https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival |
| Primary OS p-value minus significance threshold | 0.0122 p | 2025-09-07 | https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival |
| HARMONi primary median OS: ivonescimab plus chemotherapy and chemotherapy | 16.8,14 months | 2025-09-07 | https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival |
| HARMONi later post hoc OS HR and corresponding risk reduction | 0.76,24 HR; % | 2026-11-04 | https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/default.aspx |
| Original license execution date and territories | 2022-12-05; US, Canada, Europe, Japan date; territories | 2026-07-23 | https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm |
| Original license upfront payment and maximum total value | 500,5000 USD million | 2026-07-23 | https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm |
| 2024 expansion upfront payment and additional commercial milestones | 15,55 USD million | 2026-07-23 | https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm |
| Cumulative upfront payments, regulatory milestones and sales milestones after expansion | 515,1050,3505 USD million | 2026-07-23 | https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm |
| Maximum remaining milestones and lifetime deal value after expansion | 4555,5070 USD million | 2026-07-23 | https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm |
| Substantial doubt about going concern in financial statements as of 2026-06-30 | substantial doubt financial statement | 2026-07-23 | https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm |
| AstraZeneca investment, outstanding-share ownership and fully diluted ownership | 2000,12,10.6 USD million; %; % | 2026-09-28／2026-10-05 | https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment-summit.html |
| Merck-LaNova upfront payment, milestone ceiling and total deal ceiling | 588,2700,3288 USD million | 2024-11-14 | https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/ |
| Pfizer-3SBio upfront payment, milestone ceiling and total deal ceiling | 1250,4800,6050 USD million | 2025-05-19 | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio |
| BMS-BioNTech upfront payment, committed payments, milestone ceiling and total deal ceiling | 1500,2000,7600,11100 USD million | 2025-06-02 | https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple-Solid-Tumor-Types/default.aspx |
| Combined maximum total value of the four current agreements | 25508 USD million | 2026-07-23 | https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm |
| Sintilimab CRL date and FDA recommendation | 2022-03-24; additional multiregional non-inferiority study with OS endpoint date; recommendation | 2022-03-24 | https://investor.lilly.com/news-releases/news-release-details/lilly-announces-complete-response-letter-sintilimab-combination |
| Keytruda full-year 2025 product sales | 31641 USD million | 2026-02-03 | https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/ |
| HARMONi-3 squamous and non-squamous analysis schedule | squamous primary PFS + early interim OS Q4 2026; non-squamous PFS H1 2027 planned analyses | 2026-11-04 | https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/default.aspx |
| Five positive Phase III trials, May 2024 China approval and over 100,000 patients treated commercially in China | 5; 2024-05; >100000 trials; date; patients | 2026-11-15 | https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx |
| AP505 mechanism and license | PD-L1×VEGF; Tasly; Greater China excluding Taiwan targets; licensee; territories | 2019-07-29 | https://www.apbioinc.com/news-detail12.htm |
| HARMONi-2 head-to-head PFS advantage | HR 0.51; median 11.14 vs 5.82; p<0.0001 HR; months; p | 2024-09-08 | https://www.smmttx.com/wp-content/uploads/2024/09/2024_PR_0908_WCLC-HARMONi-2-Data-_-FINAL-7.pdf |

A drug that beat Keytruda has been turned down by the U.S. FDA.

On November 15, U.S. time, Summit Therapeutics announced that it had received a complete response letter from the FDA: the application for ivonescimab could not be approved on the current data.[1] Invented by China's Akeso, this PD-1×VEGF bispecific antibody had beaten Keytruda on progression-free survival in a head-to-head trial.[11] Pfizer, Merck and Bristol Myers Squibb subsequently committed large sums to drugs in the same class.

The FDA's reason was brief: without a statistically significant improvement in overall survival, efficacy had not been demonstrated.[1]

Many assumed that approval was only a matter of time for a drug that had beaten the market leader. This letter says something else. In the United States, slowing tumor growth is not enough; the question is whether patients live longer.

![Mechanisms of action of ivonescimab and Keytruda](https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival-en/figure-01.png)

## 01 | The gap: 0.057 versus 0.0448

The application relied on HARMONi. The trial enrolled 438 patients with EGFR-mutated non-small cell lung cancer after targeted therapy had failed. One group received ivonescimab plus chemotherapy; the other received chemotherapy alone.[2]

| Main HARMONi results | Ivonescimab plus chemotherapy versus chemotherapy |
|---|---|
| Risk of disease progression or death | Reduced by 48% |
| Risk of death (primary analysis) | Reduced by 21%, p=0.057 |
| Prespecified significance threshold | p below 0.0448 |
| Median overall survival | 16.8 months versus 14.0 months |

![HARMONi primary-analysis results](https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival-en/figure-02.png)

Cutting the risk of progression by nearly half looks impressive. The problem lies in the second row: a p-value of 0.057 against a threshold of 0.0448, a difference of 0.0122.

That was the gap.

Summit knew the threshold. The FDA had already made clear that statistically significant survival data were needed for approval in this indication.[2] Summit filed anyway, betting that longer follow-up would improve the numbers. In a later post hoc analysis, the risk of death was reduced by 24%, with consistent results in Asian and Western patients.[1]

The FDA was not persuaded. A post hoc analysis did not offer a second attempt at the original test.

## 02 | Why the FDA focused on survival

Progression-free survival (PFS) measures the time before disease progression or death. Overall survival (OS) measures how long patients live. The former can yield results within months; the latter can take years.

Many cancer drugs have won approval on PFS. But the FDA has tightened its standards in recent years, especially when most of the data come from a single country. Of HARMONi's 438 patients, 273 were enrolled in China.[2]

In 2022, Innovent and Lilly sought approval for the PD-1 inhibitor sintilimab using Chinese trial data. They, too, received a complete response letter, with the FDA recommending an additional multiregional trial.[5] Four years later, ivonescimab had stronger data and had included European and U.S. patients, yet it encountered another threshold at the same gate.

The two rejection letters carry the same message: Chinese clinical data can enter the United States, provided they are measured against U.S. standards.

## 03 | Whose money is held up?

Start with Akeso. In late 2022, it licensed the U.S., Canadian, European and Japanese rights to ivonescimab to Summit for $500 million upfront, in an original deal worth up to $5 billion.[3] Including the 2024 territory expansion, cumulative upfront payments reached $515 million, with regulatory milestones of up to $1.05 billion, sales milestones of up to $3.505 billion, and royalties on sales.[3]

The upfront cash has already been received. Following the expansion, up to $4.555 billion in milestones are tied to approvals and sales. A delay to the first U.S. approval pushes back the timetable for those payments.

Then consider Summit. The company has no marketed products and has staked its future on this one drug. Its financial statements as of the end of June this year still expressed substantial doubt about its ability to continue as a going concern.[3] In September, AstraZeneca announced a $2 billion investment, acquiring an equity stake equivalent to approximately 12.0% of outstanding shares, or approximately 10.6% on a fully diluted basis. The investment closed on October 5.[9]

It was buying into the drug's U.S. future.

Finally, look at those following behind.

| Buyer | Seller | Upfront payment | Maximum total deal value |
|---|---|---|---|
| Summit | Akeso | $515 million | $5.07 billion |
| Merck | LaNova Medicines | $588 million | $3.288 billion |
| Pfizer | 3SBio | $1.25 billion | $6.05 billion |
| Bristol Myers Squibb | BioNTech | $1.5 billion | $11.1 billion |

![Upfront payments and maximum total values of four deals](https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival-en/figure-03.png)

The maximum total values of these four PD-(L)1×VEGF deals add up to more than $25 billion.[3,7,8,13] Ivonescimab is furthest ahead. Its rejection gives those behind it an early look at the exam.

## 04 | The real test comes at year-end

This rejection concerns one indication: EGFR-mutated lung cancer after targeted therapy has failed. The patient population is limited. Ivonescimab's value depends on two other trials.

1. HARMONi-3: first-line lung cancer, with ivonescimab plus chemotherapy directly compared with Keytruda plus chemotherapy. The primary PFS analysis and an early interim OS analysis in the squamous cohort are expected in the fourth quarter of this year; the PFS analysis in the non-squamous cohort is expected in the first half of 2027.[12]
2. HARMONi-7: first-line lung cancer with high PD-L1 expression, comparing ivonescimab monotherapy with Keytruda monotherapy.[1]

Keytruda generated $31.641 billion in sales in 2025.[6]

If HARMONi-3 wins on survival, today's rejection letter will become a passing episode. If it again wins only on PFS while narrowly missing on survival, the entire PD-1×VEGF field will need to be revalued.

Summit says that it and Akeso have five positive Phase III trials and remain confident in the drug.[1] In China, more than 100,000 patients have received ivonescimab since its launch in May 2024.[1]

![Ivonescimab licensing, approval and clinical-readout timeline](https://drugnews.com.tw/assets/articles/akeso-summit-ivonescimab-fda-crl-overall-survival-en/figure-04.png)

## 05 | Three lessons for Taiwan's bispecific developers

For Taiwanese companies seeking to license drugs to Europe or the United States, the letter offers three reminders.

1. Include overall survival among the primary endpoints from the start, and agree with the FDA in advance on how statistical significance thresholds will be allocated.
2. Do not enroll patients only in Asia. HARMONi included European and U.S. patients and still faced questions about survival.
3. When licensing milestones are tied to U.S. approval, valuation should allow for a scenario involving one rejection and a two-year delay.

Taiwan's AP Biosciences also has a PD-L1×VEGF bispecific, AP505. It has licensed the Greater China rights, excluding Taiwan, to Tasly.[10]

The 0.0122 between 0.057 and 0.0448 has left a drug that beat the market leader waiting another round. The FDA rejected this data package; the drug's test is not over. The year-end HARMONi-3 readout will be the first formal U.S. test for PD-1×VEGF.

This article provides industry and company analysis and does not constitute investment or medical advice.

## References

1. Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application | Summit Therapeutics | 2026-11-15 | https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx
2. Summit's global PD-1xVEGF data challenge regional consistency claims but show new promising survival trend | Fierce Biotech | 2025-09-07 | https://www.fiercebiotech.com/pharma/summit-global-pd-1xvegf-data-challenge-regional-consistency-claims-new-promising-survival
3. Summit Therapeutics Form 10-Q (as of 2026-06-30) | U.S. Securities and Exchange Commission | 2026-07-23 | https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000068/smmt-20260630.htm
4. FDA won't approve Summit, Akeso's ivonescimab | pharmaphorum | 2026-11-15 | https://pharmaphorum.com/news/fda-wont-approve-summit-akesos-ivonescimab
5. Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy | Eli Lilly | 2022-03-24 | https://investor.lilly.com/news-releases/news-release-details/lilly-announces-complete-response-letter-sintilimab-combination
6. Merck Highlights Progress Advancing Broad, Diverse Pipeline | Merck | 2026-02-03 | https://www.merck.com/news/merck-highlights-progress-advancing-broad-diverse-pipeline/
7. Merck Enters into Exclusive Global License for LM-299 | Merck | 2024-11-14 | https://www.merck.com/news/merck-enters-into-exclusive-global-license-for-lm-299-an-investigational-anti-pd-1-vegf-bispecific-antibody-from-lanova-medicines-ltd/
8. Pfizer Enters into Exclusive Licensing Agreement with 3SBio | Pfizer | 2025-05-19 | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-exclusive-licensing-agreement-3sbio
9. AstraZeneca announces strategic equity investment in Summit; completes investment | AstraZeneca | 2026-09-28/2026-10-05 | https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-equity-investment-summit.html; https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-completes-equity-investment-in-summit-therapeutics.html
10. AP505 Greater China rights, excluding Taiwan, licensed to Tasly | AP Biosciences | 2019-07-29 | https://www.apbioinc.com/news-detail12.htm
11. Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab | Summit Therapeutics | 2024-09-08 | https://www.smmttx.com/wp-content/uploads/2024/09/2024_PR_0908_WCLC-HARMONi-2-Data-_-FINAL-7.pdf
12. Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 | Summit Therapeutics | 2026-11-04 | https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/default.aspx
13. BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership for BNT327 | Bristol Myers Squibb | 2025-06-02 | https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Announce-Global-Strategic-Partnership-to-Co-Develop-and-Co-Commercialize-Next-generation-Bispecific-Antibody-Candidate-BNT327-Broadly-for-Multiple-Solid-Tumor-Types/default.aspx
